Skip to content
To the full analysis

Tandem Diabetes Care stock: balance sheet and debt

TNDM
$17.51Closing price of 12 Nov 2026MEQIRI Score 43 out of 100

Tandem Diabetes Care has a debt to equity ratio of 2.86.

Daily figure as of 13 Nov 2026

Debt / Equity
2.86
Interest coverage
−24.3x
Current ratio
2.55
Cash & equivalents
$292.67M
Total assets
$881.11M
Equity ratio
17.6%
Goodwill
not reported separately
Net debt
$151.81M

Total assets and equity ratio

How large the balance sheet of Tandem Diabetes Care, Inc. is, how much of it is equity and how much is goodwill from acquisitions.

Equity ratio

Figures as a table
YearTotal assetsGoodwill and intangible assetsof which goodwillEquity ratioNet debt
2011$13.98Mnot reported separatelynot reported separately−510.1%$4.2M
2012$39.82M$3.02Mnot split out−266.3%−$12.96M
2013$162.22M$2.7Mnot split out71.2%−$100.08M
2014$106.46M$2.44Mnot split out51.3%−$37.84M
2015$125.12M$2.11Mnot split out50.7%−$41.44M
2016$112.39M$1.78Mnot split out−5.3%$25.42M
2017$95.35M$1.46Mnot split out−30.6%$62.36M
2018$206.29M$1.13Mnot split out63.6%−$129.03M
2019$326.11M$777Knot split out59.8%−$156.08M
2020$716.42M$8.81Mnot split out51.1%−$256.62M
2021$905.14M$6.64Mnot split out47.9%−$309.14M
2022$1.05B$4.63Mnot split out41.8%−$197.02M
2023$952.66M$2.78Mnot split out32.9%−$52.25M
2024$967.66M$925Knot split out27.2%$35.24M
2025$881.11Mnot reported separatelynot reported separately17.6%$151.81M

The equity ratio divides total equity, including non-controlling interests, by total assets. Net debt is debt minus cash and short-term investments; a negative figure means cash exceeds debt. In years without separate goodwill, the table shows the sum of goodwill and intangible assets, because the data do not list goodwill separately there.

Equity and debt

What the company owns and owes

  • Cash & equivalents
  • Equity
  • Debt
Figures as a table
YearCash & equivalentsEquityDebtDebt / Equity
2011$8.66M−$71.29M$12.86M−0.18
2012$17.16M−$106.05M$4.2M−0.04
2013$129.48M$115.54M$29.4M0.25
2014$67.28M$54.57M$29.44M0.54
2015$71.11M$63.47M$29.67M0.47
2016$53.54M−$5.93M$78.96M−13.32
2017$14.18M−$29.15M$76.54M−2.63
2018$129.03M$131.28M$00
2019$176.46M$194.98M$20.38M0.1
2020$484.94M$366.31M$228.32M0.62
2021$623.81M$433.11M$314.67M0.73
2022$616.9M$439.95M$419.88M0.95
2023$467.91M$313.63M$415.67M1.33
2024$438.33M$263.1M$473.57M1.8
2025$292.67M$155.17M$444.48M2.86

Data status and sources

Score
Daily value of 13 Nov 2026, recalculated nightly
Price
Closing price of 12 Nov 2026
Latest annual report
Fiscal year 2025, period end 31 Dec 2025
Source
Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.

Mandatory disclosures for this rating

  • ; time horizon around 12 months
  • Rated Weak, published since 7 Nov 2026 (in the score history since 30 Apr 2022)
  • Valuation signal Fairly valued since 7 Nov 2026
  • End-of-day prices, metrics cached for up to 24 hours
  • Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
  • Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
  • Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.

MEQIRI counts visits without cookies. With your consent we remember for 90 days where you came from, also in your account, count page changes and time on page, recognise your next visit and load the Meta Pixel, which measures our advertising. You can withdraw your consent at any time under Cookie settings. Privacy